The Filings Report

Teva Pharmaceutical Industries Limited American Depositary Shares

TEVANYSECIK 818686Healthcare / Drug Manufacturersfiscal year ends December42 quarters since 2016

Revenue, Q2 FY2026
$4.1B
no year-earlier figure
Net income
−$576M
−304.3% on Q2 FY2025
Free cash flow
$307M
+134.4% on Q2 FY2025
Diluted EPS
$-0.49
−304.2% on Q2 FY2025
Revenue, TTM
—
trailing four quarters
Net margin, TTM
—
net income $706M
Free cash flow, TTM
$1.3B
$1.9B less $550M capex
Cash and equivalents
$3.7B
long-term debt —, Jun 30, 2026
Shares, 12-month change
+1.6%
1.17B shares, Jun 30, 2026
Buybacks, TTM
—
no yield
Dividends, TTM
—
no yield
Market value
$49.0B
at the close, buybacks

Latest quarter Q2 FY2026, filed July 29, 2026. Trailing figures sum the latest four quarters. Market values at the latest close, from a market data vendor.

In Q2 FY2026, the quarter ended June 30, 2026, Teva Pharmaceutical Industries Limited American Depositary Shares reported revenue of $4.1B, and net loss of $576M (−304.3%). Net income this quarter is driven by non-operating items: −$224M of other income against −$231M of operating income, so it reflects gains or losses outside the operations. Operating margin was −5.6%. Free cash flow, operating cash flow less capital expenditures, was $307M ($411M less $104M). Diluted earnings per share were $-0.49.

The last 16 quarters

Q3 FY2022 to Q2 FY2026, through the filing of July 29, 2026.

Revenue and net incomeRevenueNet income
−$2B$0$2B$4B$6BQ3'22, Revenue: $3.6BQ3'22, Net income: $61MQ3'22Q4'22, Revenue: $3.9BQ4'22, Net income: −$1.3BQ4'22Q1'23, Revenue: $3.7BQ1'23, Net income: −$220MQ1'23Q2'23, Revenue: $3.9BQ2'23, Net income: −$872MQ2'23Q3'23, Revenue: $3.9BQ3'23, Net income: $69MQ3'23Q4'23, Revenue: $4.5BQ4'23, Net income: $463MQ4'23Q1'24, Revenue: $3.8BQ1'24, Net income: −$139MQ1'24Q2'24, Revenue: $4.2BQ2'24, Net income: −$846MQ2'24Q3'24, Revenue: $4.3BQ3'24, Net income: −$437MQ3'24Q4'24, Revenue: $4.2BQ4'24, Net income: −$217MQ4'24Q1'25, Net income: $214MQ1'25Q2'25, Net income: $282MQ2'25Q3'25, Net income: $433MQ3'25Q4'25, Net income: $480MQ4'25Q1'26, Revenue: $4.0BQ1'26, Net income: $369MQ1'26Q2'26, Revenue: $4.1BQ2'26, Net income: −$576MQ2'26−$2B$0$2B$4B$6BQ3'22, Revenue: $3.6BQ3'22, Net income: $61MQ4'22, Revenue: $3.9BQ4'22, Net income: −$1.3BQ4'22Q1'23, Revenue: $3.7BQ1'23, Net income: −$220MQ2'23, Revenue: $3.9BQ2'23, Net income: −$872MQ2'23Q3'23, Revenue: $3.9BQ3'23, Net income: $69MQ4'23, Revenue: $4.5BQ4'23, Net income: $463MQ4'23Q1'24, Revenue: $3.8BQ1'24, Net income: −$139MQ2'24, Revenue: $4.2BQ2'24, Net income: −$846MQ2'24Q3'24, Revenue: $4.3BQ3'24, Net income: −$437MQ4'24, Revenue: $4.2BQ4'24, Net income: −$217MQ4'24Q1'25, Net income: $214MQ2'25, Net income: $282MQ2'25Q3'25, Net income: $433MQ4'25, Net income: $480MQ4'25Q1'26, Revenue: $4.0BQ1'26, Net income: $369MQ2'26, Revenue: $4.1BQ2'26, Net income: −$576MQ2'26

Net income losses drawn in red.

Free cash flow
−$500M$0$500M$1.0B$1.5BQ3'22, Free cash flow: $421MQ3'22Q4'22, Free cash flow: $831MQ4'22Q1'23, Free cash flow: −$284MQ1'23Q2'23, Free cash flow: $205MQ2'23Q3'23, Free cash flow: −$144MQ3'23Q4'23, Free cash flow: $1.1BQ4'23Q1'24, Free cash flow: −$248MQ1'24Q2'24, Free cash flow: $6MQ2'24Q3'24, Free cash flow: $545MQ3'24Q4'24, Free cash flow: $446MQ4'24Q1'25, Free cash flow: −$232MQ1'25Q2'25, Free cash flow: $131MQ2'25Q3'25, Free cash flow: $233MQ3'25Q4'25, Free cash flow: $1.0BQ4'25Q1'26, Free cash flow: −$208MQ1'26Q2'26, Free cash flow: $307MQ2'26−$500M$0$500M$1.0B$1.5BQ3'22, Free cash flow: $421MQ4'22, Free cash flow: $831MQ4'22Q1'23, Free cash flow: −$284MQ2'23, Free cash flow: $205MQ2'23Q3'23, Free cash flow: −$144MQ4'23, Free cash flow: $1.1BQ4'23Q1'24, Free cash flow: −$248MQ2'24, Free cash flow: $6MQ2'24Q3'24, Free cash flow: $545MQ4'24, Free cash flow: $446MQ4'24Q1'25, Free cash flow: −$232MQ2'25, Free cash flow: $131MQ2'25Q3'25, Free cash flow: $233MQ4'25, Free cash flow: $1.0BQ4'25Q1'26, Free cash flow: −$208MQ2'26, Free cash flow: $307MQ2'26

Operating cash flow less capital expenditures; negative quarters in red.

Cash and equivalents against long-term debtCash and equivalentsLong-term debt
$0$1B$2B$3B$4BQ3'22, Cash and equivalents: $2.2BQ3'22Q4'22, Cash and equivalents: $2.8BQ4'22Q1'23, Cash and equivalents: $2.1BQ1'23Q2'23, Cash and equivalents: $2.7BQ2'23Q3'23, Cash and equivalents: $2.2BQ3'23Q4'23, Cash and equivalents: $3.2BQ4'23Q1'24, Cash and equivalents: $3.0BQ1'24Q2'24, Cash and equivalents: $2.3BQ2'24Q3'24, Cash and equivalents: $3.3BQ3'24Q4'24, Cash and equivalents: $3.3BQ4'24Q1'25, Cash and equivalents: $1.7BQ1'25Q2'25, Cash and equivalents: $2.2BQ2'25Q3'25, Cash and equivalents: $2.2BQ3'25Q4'25, Cash and equivalents: $3.6BQ4'25Q1'26, Cash and equivalents: $3.7BQ1'26Q2'26, Cash and equivalents: $3.7BQ2'26$0$1B$2B$3B$4BQ3'22, Cash and equivalents: $2.2BQ4'22, Cash and equivalents: $2.8BQ4'22Q1'23, Cash and equivalents: $2.1BQ2'23, Cash and equivalents: $2.7BQ2'23Q3'23, Cash and equivalents: $2.2BQ4'23, Cash and equivalents: $3.2BQ4'23Q1'24, Cash and equivalents: $3.0BQ2'24, Cash and equivalents: $2.3BQ2'24Q3'24, Cash and equivalents: $3.3BQ4'24, Cash and equivalents: $3.3BQ4'24Q1'25, Cash and equivalents: $1.7BQ2'25, Cash and equivalents: $2.2BQ2'25Q3'25, Cash and equivalents: $2.2BQ4'25, Cash and equivalents: $3.6BQ4'25Q1'26, Cash and equivalents: $3.7BQ2'26, Cash and equivalents: $3.7BQ2'26

Positions at each quarter end, as filed; short-term investments are not included.

Income statement

Last eight quarters, newest first, through Q2 FY2026 filed July 29, 2026.

Teva Pharmaceutical Industries Limited American Depositary Shares income statement, quarterly
Millions of dollarsQ2 FY2026ended Jun 30, 2026filed Jul 29, 2026Q1 FY2026ended Mar 31, 2026filed Apr 29, 2026Q4 FY2025ended Dec 31, 2025filed Feb 3, 2026Q3 FY2025ended Sep 30, 2025filed Nov 5, 2025Q2 FY2025ended Jun 30, 2025filed Jul 30, 2025Q1 FY2025ended Mar 31, 2025filed May 7, 2025Q4 FY2024ended Dec 31, 2024filed Feb 5, 2025Q3 FY2024ended Sep 30, 2024filed Nov 6, 2024YoYQ2 FY2026vs Q2 FY2025
Revenue4,1423,982withheldwithheldwithheldwithheld4,2294,332—
Cost of revenue1,9892,0112,0562,1762,0742,0142,1092,183−4.1%
Gross profit2,1531,9722,6562,3042,1021,8772,1212,148+2.4%
Research and development—————————
Selling, general and administrative317304367317305297302298+3.9%
Operating income(231)652300882455519(29)(51)−150.8%
Other income (expense)(224)(216)(220)(237)(252)(225)(218)(272)+11.1%
Pretax income(455)43780646203294(247)(324)−324.1%
Income tax12167(390)214(78)742869+255.1%
Net income(576)369480433282214(217)(437)−304.3%
Diluted EPS ($)(0.49)0.31—0.370.240.18—(0.39)−304.2%
Diluted shares (millions)1,1651,179—1,1641,1611,159—1,133—

Fourth quarters are the fiscal year less the first nine months when the filer reports no discrete fourth quarter, and are marked. Diluted EPS is never derived, so a derived quarter shows none. Italic figures are derived.

Balance sheet

Last eight quarters, newest first, through Q2 FY2026 filed July 29, 2026.

Teva Pharmaceutical Industries Limited American Depositary Shares balance sheet, quarterly
Millions of dollarsQ2 FY2026ended Jun 30, 2026filed Jul 29, 2026Q1 FY2026ended Mar 31, 2026filed Apr 29, 2026Q4 FY2025ended Dec 31, 2025filed Feb 3, 2026Q3 FY2025ended Sep 30, 2025filed Nov 5, 2025Q2 FY2025ended Jun 30, 2025filed Jul 30, 2025Q1 FY2025ended Mar 31, 2025filed May 7, 2025Q4 FY2024ended Dec 31, 2024filed Feb 5, 2025Q3 FY2024ended Sep 30, 2024filed Nov 6, 2024YoYQ2 FY2026vs Q2 FY2025
Cash and equivalents3,6553,7413,5562,2032,1611,6973,3003,319+69.1%
Short-term investments—————————
Total current assets13,76013,71013,94612,73612,62011,52812,55212,314+9.0%
Total assets39,85740,04040,74839,85640,13138,41539,32641,758−0.7%
Total current liabilities15,64613,53213,45611,49111,86111,15712,79613,797+31.9%
Long-term debt—————————
Total liabilities32,10031,80932,83432,60233,29732,14633,60635,375−3.6%
Stockholders’ equity7,7538,2287,9107,2506,8276,2625,3736,065+13.6%
Shares outstanding (millions)1,1651,1641,1501,1471,1471,1471,1341,133—

Positions at each period end. Nothing on this statement is derived. Long-term debt is the filed noncurrent line only; no total-debt composite is constructed across filers. Italic figures are derived.

Cash flow statement

Last eight quarters, newest first, through Q2 FY2026 filed July 29, 2026.

Teva Pharmaceutical Industries Limited American Depositary Shares cash flow statement, quarterly
Millions of dollarsQ2 FY2026ended Jun 30, 2026filed Jul 29, 2026Q1 FY2026ended Mar 31, 2026filed Apr 29, 2026Q4 FY2025ended Dec 31, 2025filed Feb 3, 2026Q3 FY2025ended Sep 30, 2025filed Nov 5, 2025Q2 FY2025ended Jun 30, 2025filed Jul 30, 2025Q1 FY2025ended Mar 31, 2025filed May 7, 2025Q4 FY2024ended Dec 31, 2024filed Feb 5, 2025Q3 FY2024ended Sep 30, 2024filed Nov 6, 2024YoYQ2 FY2026vs Q2 FY2025
Operating cash flow411(40)1,158369227(105)575693+81.1%
Capital expenditures10416814213696127129148+8.3%
Free cash flow (CFO − capex)307(208)1,016233131(232)446545+134.4%
Depreciation and amortization241239260249251244269259−4.0%
Share repurchases—————————
Dividends paid—————————

10-Qs file cash flows as year-to-date totals, so quarterly figures are differenced from consecutive filings and marked. Free cash flow is operating cash flow less capital expenditures, computed from the two filed lines. Italic figures are derived.

Annual statements

Every fiscal year filed, newest first, through FY2025 filed February 3, 2026.

Income statement

Teva Pharmaceutical Industries Limited American Depositary Shares income statement, annual
Millions of dollarsFY2025ended Dec 31, 2025filed Feb 3, 2026FY2024ended Dec 31, 2024filed Feb 5, 2025FY2023ended Dec 31, 2023filed Feb 12, 2024FY2022ended Dec 31, 2022filed Feb 10, 2023FY2021ended Dec 31, 2021filed Feb 9, 2022FY2020ended Dec 31, 2020filed Feb 10, 2021FY2019ended Dec 31, 2019filed Feb 21, 2020FY2018ended Dec 31, 2018filed Feb 19, 2019FY2017ended Dec 31, 2017filed Feb 12, 2018FY2016ended Dec 31, 2016filed Feb 12, 2018FY2015ended Dec 31, 2015filed Feb 12, 2018
Revenue17,25816,54415,84614,92515,87816,65916,88718,27121,85321,90319,652
Cost of revenue8,3208,4818,2007,9528,2848,9339,3519,97511,23710,2508,296
Gross profit8,9388,0647,6456,9737,5947,7267,5378,29610,61511,65311,356
Research and development———98———11417542235
Selling, general and administrative1,2871,1611,1621,1801,0991,1731,1921,2981,4511,3901,360
Operating income2,157(303)433(2,197)1,716(3,572)(443)(1,637)(17,484)2,1543,352
Other income (expense)(934)(981)(1,057)(966)(1,058)(834)(822)(959)(895)(1,330)(1,000)
Pretax income1,223(1,284)(624)(3,163)658(4,406)(1,265)(2,596)(18,379)8242,352
Income tax(180)676(7)(643)211(168)(278)(195)(1,933)521634
Net income1,410(1,639)(559)(2,446)417(3,990)(999)(2,150)(16,265)3291,588
Diluted EPS ($)1.21(1.45)(0.50)(2.20)0.38(3.64)(0.91)(2.35)(16.26)0.071.82
Diluted shares (millions)1,1631,1311,1191,1101,1071,0951,0911,0211,0161*—

Balance sheet

Teva Pharmaceutical Industries Limited American Depositary Shares balance sheet, annual
Millions of dollarsFY2025ended Dec 31, 2025filed Feb 3, 2026FY2024ended Dec 31, 2024filed Feb 5, 2025FY2023ended Dec 31, 2023filed Feb 12, 2024FY2022ended Dec 31, 2022filed Feb 10, 2023FY2021ended Dec 31, 2021filed Feb 9, 2022FY2020ended Dec 31, 2020filed Feb 10, 2021FY2019ended Dec 31, 2019filed Feb 21, 2020FY2018ended Dec 31, 2018filed Feb 19, 2019FY2017ended Dec 31, 2017filed Feb 12, 2018FY2016ended Dec 31, 2016filed Feb 12, 2018FY2015ended Dec 31, 2015filed Feb 12, 2018
Cash and equivalents3,5563,3003,2262,8012,1652,1771,9751,7829639886,946
Short-term investments———————————
Total current assets13,94612,55212,48512,05112,57313,00513,46413,79415,38217,228—
Total assets40,74839,32643,47944,01147,66650,64057,47060,68370,61593,057—
Total current liabilities13,45612,79612,24711,46911,02713,16413,67414,32217,92118,488—
Long-term debt————————28,82932,524—
Total liabilities32,83433,60635,35335,41336,42239,57942,40744,88951,87058,064—
Stockholders’ equity7,9105,3737,5067,80410,27810,02613,97214,70717,35933,337—
Shares outstanding (millions)1,1501,1341,1211,1111,1031,0971,0921,0891,0181,123—

Cash flow statement

Teva Pharmaceutical Industries Limited American Depositary Shares cash flow statement, annual
Millions of dollarsFY2025ended Dec 31, 2025filed Feb 3, 2026FY2024ended Dec 31, 2024filed Feb 5, 2025FY2023ended Dec 31, 2023filed Feb 12, 2024FY2022ended Dec 31, 2022filed Feb 10, 2023FY2021ended Dec 31, 2021filed Feb 9, 2022FY2020ended Dec 31, 2020filed Feb 10, 2021FY2019ended Dec 31, 2019filed Feb 21, 2020FY2018ended Dec 31, 2018filed Feb 19, 2019FY2017ended Dec 31, 2017filed Feb 12, 2018FY2016ended Dec 31, 2016filed Feb 12, 2018FY2015ended Dec 31, 2015filed Feb 12, 2018
Operating cash flow1,6491,2471,3681,5907981,2167482,4462,2253,8905,542
Capital expenditures501498526548562578525651874901772
Free cash flow (CFO − capex)1,1487498421,0422366382231,7951,3512,9894,770
Depreciation and amortization1,0021,0591,1531,3081,3301,5571,7221,8422,1121,5241,308
Share repurchases————————00439
Dividends paid———————129011,3031,155

Insider activity

Form 4 filings by officers, directors and 10% owners, November 1, 2024 to November 1, 2026. Only open-market purchases and sales count as buys and sells; awards, exercises, tax withholding and gifts are listed in grey and never counted.

Bought, three months
$0
0 purchases by 0 insiders; officers and directors $0
Sold, three months
$17M
11 sales by 8 insiders; officers and directors $17M
Bought, twelve months
$0
0 purchases by 0 insiders; officers and directors $0
Sold, twelve months
$113M
58 sales by 14 insiders; officers and directors $113M

The last 25 transactions

TradedInsiderRoleTransactionSharesPriceValueHeld afterFiled
Sep 18, 2026Savage BrianInterim Chief Legal Officeroption exercise4,503$34.70$156K15,842Sep 22, 2026
Sep 18, 2026Savage BrianInterim Chief Legal Officeropen-market sale4,503$38.69$174K11,339Sep 22, 2026
Sep 18, 2026Savage BrianInterim Chief Legal Officeropen-market sale2,525$39.15$99K8,814Sep 22, 2026
Sep 18, 2026Savage BrianInterim Chief Legal Officeropen-market sale314$38.70$12K8,500Sep 22, 2026
Sep 18, 2026Mignone RobertoDirectoropen-market saleindirect367,600$39.06$14M0Sep 22, 2026
Aug 21, 2026Weiss AmirChief Accounting Officeropen-market sale6,945$37.61$261K13,071Aug 25, 2026
Aug 21, 2026Weiss AmirChief Accounting Officeroption exercise2,500$19.61$49K15,571Aug 25, 2026
Aug 21, 2026Weiss AmirChief Accounting Officeropen-market sale2,500$37.63$94K13,071Aug 25, 2026
Aug 21, 2026Satchi-Fainaro RonitDirectoropen-market sale415$37.25$15K111,986Aug 25, 2026
Aug 17, 2026Lippman EvanEVP, Business Developmentopen-market sale10b5-118,600$36.57$680K25,591Aug 19, 2026
Aug 5, 2026Zaks Tal ZviDirectoropen-market sale17$34.87$59373,247Aug 10, 2026
Aug 3, 2026Jover PlacidSee "Remarks"option exercise12,827——19,601Aug 5, 2026
Aug 3, 2026Jover PlacidSee "Remarks"open-market sale10b5-112,827$34.88$447K6,774Aug 5, 2026
Aug 3, 2026Hughes Eric ASee "Remarks"option exercise52,744——160,455Aug 5, 2026
Aug 3, 2026Hughes Eric ASee "Remarks"open-market sale10b5-125,578$34.88$892K134,877Aug 5, 2026
Jun 18, 2026Shields MatthewEVP, Global Operationsopen-market sale9,989$32.19$322K0Jun 22, 2026
Jun 11, 2026Kalif Eliyahu SharonEVP, Chief Financial Officeropen-market sale10b5-1106,563$34.10$4M65,621Jun 16, 2026
Jun 5, 2026Barer Sol JDirectoroption exercise21,739——448,011Jun 8, 2026
Jun 5, 2026Lichtenstein ChenDirectoroption exercise14,492——19,296Jun 8, 2026
Jun 5, 2026Crane Rosemary ADirectoroption exercise14,492——127,739Jun 8, 2026
Jun 5, 2026Elstein AmirDirectoroption exercise14,492——2MJun 8, 2026
Jun 5, 2026Lieberman Gerald MDirectoroption exercise14,492——130,149Jun 8, 2026
Jun 5, 2026Nisen PerryDirectoroption exercise14,492——119,807Jun 8, 2026
Jun 5, 2026Satchi-Fainaro RonitDirectoroption exercise14,492——112,401Jun 8, 2026
Jun 5, 2026Zaks Tal ZviDirectoroption exercise14,492——73,264Jun 8, 2026

Full insider history for Teva Pharmaceutical Industries Limited American Depositary Shares, or insider activity across all companies. A record of filings, not a recommendation.

Tracked funds holding it

3 of the tracked managers held TEVA in their latest 13F filing, through August 14, 2026. Weight is the share of the fund’s reported portfolio. How the funds have traded TEVA by quarter.

FundManagerQuarterValueSharesWeightMove
Greenlight CapitalDavid EinhornQ2 2026$98M3M2.50%held −0.8%
Duquesne Family OfficeStanley DruckenmillerQ2 2026$21M624,9990.41%trimmed −73.7%
Baron Capital GroupRon BaronQ2 2026$5M138,9870.01%added +6.9%

Sources

Fiscal year ends in month 12; periods are labeled with the issuer's own fiscal calendar. Values are as most recently filed (restatements apply; per-share values are on current split basis per the connector's split table, flagged in adjusted). Flow items flagged in `derived` were computed (Q4 = FY − nine months; quarterly cash flow differenced from year-to-date filings) rather than read from a filing. `reconciliation.repaired` lists periods where a full-year figure was filed in a quarter slot: that row was dropped and the quarter rebuilt from the annual figure. `reconciliation.quarantined` lists periods where four filed quarters do not sum to the filed year — those quarterly values are withheld, so a blank there is a withholding rather than an absence of reporting.

Filer
TEVA PHARMACEUTICAL INDUSTRIES LIMITED, CIK 818686 on EDGAR
Extract generated
November 1, 2026
Withheld
3 line-years whose four quarters do not sum to the filed year: gross profit FY2016, revenue FY2017, revenue FY2025
Repaired
2 quarters where a full-year figure was filed in a quarter slot and the quarter was rebuilt: pretax income FY2020, income tax FY2023
XBRL concepts behind each line

Income statement

Revenue: RevenueFromContractWithCustomerExcludingAssessedTax, Revenues, SalesRevenueNet
Cost of revenue: CostOfGoodsAndServicesSold
Gross profit: GrossProfit
Research and development: ResearchAndDevelopmentExpense
Selling, general and administrative: GeneralAndAdministrativeExpense
Operating income: OperatingIncomeLoss
Other income (expense): NonoperatingIncomeExpense
Pretax income: IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
Income tax: IncomeTaxExpenseBenefit
Net income: NetIncomeLoss
Diluted EPS ($): EarningsPerShareDiluted
Diluted shares (millions): WeightedAverageNumberOfDilutedSharesOutstanding

Balance sheet

Cash and equivalents: CashAndCashEquivalentsAtCarryingValue
Short-term investments: not filed
Total current assets: AssetsCurrent
Total assets: Assets
Total current liabilities: LiabilitiesCurrent
Long-term debt: LongTermDebt
Total liabilities: Liabilities
Stockholders’ equity: StockholdersEquity
Shares outstanding (millions): dei:EntityCommonStockSharesOutstanding

Cash flow statement

Operating cash flow: NetCashProvidedByUsedInOperatingActivities
Capital expenditures: PaymentsToAcquireProductiveAssets, PaymentsToAcquirePropertyPlantAndEquipment
Free cash flow (CFO − capex): not filed
Depreciation and amortization: DepreciationAndAmortization
Share repurchases: PaymentsForRepurchaseOfCommonStock
Dividends paid: PaymentsOfDividendsCommonStock

The data

The statements on this page as files, generated November 1, 2026.

JSON file
/data/financials/TEVA.json